POSTER SESSION V Wednesday, February 15, 2006   —  9:30 AM - 12:00 Noon Exhibit Level BREAST PATHOLOGY 21 Sentinel Lymph Node (SLN) Sampling in Patients With Core Biopsy Diagnosis of Ductal Carcinoma IN SITU (DCIS): UT M.D. Anderson Cancer Center Experience and Future Recommendations (127) L Huo, N Sneige, A Lopez, E Resetkova - The UT MD Anderson Cancer Center, Houston, TX 22 Significance Of Intramammary Lymph Nodes In The Staging Of Breast Cancer: Correlation With Tumor Characteristics And Outcome (157) A Nassar, C Cohen, G Cotsonis, G Carlson - Emory University Hospital, School of Public Health, Atlanta, GA 23 A Newly Proposed Semi-Automated Method of Grading Ductal Carcinoma In Situ of the Breast (187) O Tawfik, MK Davis, J Clark, F Fan, I Damjanov, A Namiq, P Thomas, BF Kimler - Kansas University Medical Center, Kansas, KS 24 A Comparative Study Between New Rabbit Monoclonal Antibodies and Mouse Monoclonal Antibodies Anti-Estrogen Receptor in Breast Cancer (118) H Gobbi, CB Nunes, RM Rocha, GS Rocha, FF Sanches, FN Oliveira, VP Andrade - Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Fleury Institute, Sao Paulo, SP, Brazil 25 Comparison Of Breast Prognostic Markers When Obtained With The Cassi Biopsy Device Versus A 14 G Needle Core Biopsy (90) KJ Bloom, P Whitworth, C Mixon - CLARiENT Inc; Nashville Breast Center; Baptist Hospital, Nashville, TN 26 Oestrogen Receptors (± And ²) In Primary And Recurrent Breast Cancer (78) TA Adegbola, V Ulman, R Salman, OA Ipadeola, CE Connolly - St James's Hospital, Dublin, Ireland; Clinical Science Instsitute, NUI, University College Hospital, Galway, Ireland 27 Estrogen Receptor Negative Breast Cancer: Biology and Phenotypic Characteristics (97) Y Choi - Yale University School of Medicine, New Haven, CT 28 HER2 Amplification in Tubular Carcinoma of the Breast (162) J Oakley III, RR Tubbs, J Crowe, B Sebek, GT Budd, RJ Patrick, GW Procop - Marshall University, Huntington, WV; The Cleveland Clinic Foundation and the Lerner College of Medicine, Cleveland, OH 29 Should All Positive Immunohistochemistry (IHC) HER-2/neu Over-Expression be Tested by Fluorescent In Situ Hybridization (FISH) in Breast Cancer cases Patients? 5-Year Community Based Study (81) AB Ambaye, A Ciampa, M Evans, W Trotman, T Suppan, S Naud, DL Weaver - Fletcher Allen Health Care; University of Vermont; Vermont Cancer Center, Burlington, VT 30 Association Of Her2/Neu With Complete Response In Breast Carcinoma With Neoadjuvant Chemotherapy (164) G Peiró, E Adrover, FI Aranda, C Alenda, A Payá, J Seguí - Hospital General Universitari, Alacant, Spain 31 CISH Is An Alternative Method To FISH In Determining HER2/neu Status On Core Biopsies (161) S Nofech-Mozes, M Clemons, W Hanna - Sunnybrook and Women's College Health Science Centre, Toronto, ON, Canada 32 Breast Cancers with Polysomy Chromosome 17: Its Frequency And Effects on the Ploidy And HER-2/neu Expression (169) MR Quddus, MM Steinhoff, CJ Sung, L Rashid, H Bai, U Tantravahi - Women & Infants Hospital, Brown Medical School, Providence, RI 33 Comparison of Different Commercial In Situ Hybridization (ISH) Kits for HER-2 Testing in Breast Cancer. Looking for the Accurate Cut Off (165) FM Penault-Llorca, F Mishellany, N Lagarde, A Cayre - Centre Jean Perrin, Clermont-Ferrand, France 34 Intratumoral Heterogeneity of HER2/neu in Breast Cancer - A Rare Event or an Overlooked Phenomenon? (123) W Hanna, S Nofech-Mozes, H Kahn - Sunnybrook and Women's College Health Science Centre, Toronto, ON, Canada 35 Correlation of Her2/neu Overexpression (IHC) with Gene Amplification (FISH), and its relation to Chromosome 17 Aneuploidy: A 5 Year Experience with Invasive Ductal Carcinoma (170) A Radhakrishnan, A Nassar, M Lewis, C Phillips, C Cohen - Emory University Hospital, Atlanta, GA 36 The Experience of Breast Cancer HER-2/neu Testing by Fluorescence In-Situ Hybridization in a Community Hospital: Advantages of Community Testing Over Central Testing (197) H Yaziji, R Derhagopian, N Cartagena, D Rubin, A Renshaw, R Shah, E Gould - Baptist Hospital, Miami, FL 37 Correction For Chromosome 17 Is Critical For Determination Of True HER2 Gene Amplification Status In Breast Cancer (BC) (137) D Larsimont, V Durbecq, C Desmedt, R Salgado, L Dal Lago, L Lespagnard, T Verjat, C Sotiriou - Bordet Institute, Brussels, Belgium; BioMérieux, Marcy l'Etoile, France 38 Histologic And Immunophenotypic Features Of Estrogen Receptor, Progesterone Receptor, Her2/Neu Negative Breast Carcinomas (85) AC Baruch, E Resetkova, M Cristofanilli, N Sneige - UTMD Anderson Cancer Center, Houston, TX 39 Immunohistochemical Characterization Of Subtypes Of Male Breast Carcinoma (115) Y Ge, N Sneige, MA Eltorky, Y Gong, M Guo - UT MD Anderson Cancer Center, Houston, TX; University of Texas Medical Branch, Galveston, TX 40 Correlation of DNA Mismatch Repair Genes, Hormone Receptor Status and Proliferation Markers in Male Breast Cancer (116) S Giashuddin, H Yee, R Arju, L Chiriboga, D Silvera, F Darvishian - NYU, School of Medicine, NYU Cancer Institute, New York, NY 41 Molecular Evaluation Of Multiple Breast Carcinomas: Ipsilateral And Contralateral Metastasis Vs. Separate Primaries (112) SD Finkelstein, TC Pereira, YL Liu, RS Saad, JF Silverman - RedPath Integrated Pathology, Inc; Allegheny General Hospital, Pittsburgh, PA 42 Diagnostic And Prognostic Utility Of Molecular Markers In Bilateral Synchronous Breast Carcinoma (104) KL Denning, SD Finkelstein, RS Saad, YL Liu, X Lin, TC Pereira, JF Silverman - Alleghney General Hospital, RedPath Integrated Pathology, Inc, Pittsburgh, PA 43 Gene Expression Profiling Of NMU-Induced Rat Mammary Tumors: A Model Of Human Breast Cancer Progression (95) MM Chan, X Lu, JD Iglehart, PL Miron - Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute, Boston, MA 44 Ezrin, a Cytoskeletal Linker Protein is Expressed in a Subset of Breast Cancers and Correlates with Estrogen Receptor Expression and a More Favorable Clinical Outcome (125) DG Hicks, ST Sizemore, BJ Yoder, SM Short, NL Prescott, SM Tarr, JP Crowe, TK Choueiri, GT Budd, RR Tubbs, G Casey - The Cleveland Clinic, Cleveland, OH 45 NY-BR-1 - A Novel Differentiation Antigen of the Mammary Gland (130) AA Jungbluth, V Filonenko, I Gouth, Z Varga, H Moch, YT Chen, KJ Busam, A Nissan, I Seil, LJ Old, D Jaeger - Ludwig Institute for Cancer Research, Cornell University, Memorial Sloan-Kettering Cancer Hospital, New York, NY; Institute of Molecular Biology and Genetics, Kyiv, Ukraine; University Hospital, Zurich, Switzerland; Hadassah University Hospital Mount Scopus, Jerusalem, Israel; Georg-Speyer-Haus, Frankfurt, Germany; University Hospital, Heidelberg, Germany